Eli Lilly (LLY): FY25 Q1 earnings call, May 1, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s May 1, 2025 earnings call (FY25 Q1). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
6 matches for “Impact”; 5 quoted, at least 25 words apart.
…to meet global demand. This scientific breakthrough has the potential to eventually impact hundreds of millions of people around the world with chronic diseases. And…
…delivered earnings per share of $3.34 in Q1, inclusive of the negative impact of $1.72 from acquired IPR&D charges. This compares to earnings per share…
…carrying high risk early breast cancer. As expected, we have seen some impact from competition in early breast cancer. However, Verzenio share of market in…
…estimate that the announced tariff currently in effect will have a limited impact financially, which we have absorbed within our 2025 guide. Now I will…
…from this robust clinical development program as we continue to find the impact orforglipron can have for patients. Moving on to other R&D updates since…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-05-01:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-05-01:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP